NeuroSense Therapeutics (NRSN) Return on Capital Employed (2022 - 2024)
NeuroSense Therapeutics (NRSN) posted Return on Capital Employed of 1257.4% for Q4 2024, down 366.3% sequentially from 472.18% in Q3 2024, and up 20044.0% YoY from N/an in Q1 2024.
NeuroSense Therapeutics (NRSN) Return on Capital Employed (2022 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported Return on Capital Employed for 3 years, with the latest figure at 1257.4% in Q4 2024.
- Quarterly Return on Capital Employed rose 20044.0% year-over-year to 1257.4% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 1257.4% (up 20044.0% YoY) and the FY2025 annual result came in at 3882.66%, down 335819.0% from the prior year.
- Return on Capital Employed slipped to 1257.4% in Q4 2024 per NRSN's latest filing, from 472.18% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 628.16% in Q2 2024 and troughed at 1457.83% in Q4 2023.
- A 3-year average of 167.59% and a median of 96.7% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 130142 bps in 2023, then surged 76022 bps in 2024.
- Over 3 years, Return on Capital Employed stood at 156.41% in 2022, then slumped by 832 bps to 1457.83% in 2023, then grew by 14 bps to 1257.4% in 2024.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 1257.4%, 472.18%, and 628.16% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,257.40% |
| Sep 30, 2024 | 472.18% |
| Jun 30, 2024 | 628.16% |
| Mar 31, 2024 | 543.01% |
| Dec 31, 2023 | -1,457.83% |
| Sep 30, 2023 | -245.36% |
| Jun 30, 2023 | 0.34% |
| Mar 31, 2023 | -217.22% |
| Dec 31, 2022 | -156.41% |
| Sep 30, 2022 | -96.70% |
| Jun 30, 2022 | -56.27% |